Abstract: Provided is a composition, especially a cosmetic composition, that comprises at least one monoglyceride and at least one tartaric ester of monoglyceride, and at least one coated pigment and/or mineral filler. Also provided is the use of a coated pigment and/or coated mineral filler for improving the stability of a composition, especially a cosmetic composition comprising at least one monoglyceride and at least one diacetyl tartaric ester of monoglyceride. Further provided is a cosmetic treatment method that implements the composition of the invention.

Abstract: The present application relates to GHB formulations and methods for manufacturing the same.

Abstract: The present invention belongs to the fields of pharmaceuticals and cosmetics, and concerns on the one hand a medicament for the inhibition of and refers also on the cosmetic, non-therapeutic use for the treatment of hyperpigmentation, particularly induced by sun light radiation, preferably induced by visible light radiation.

Abstract: An implantable ocular drug delivery system can include inserting an implantable device into an eye, where the device contains therapeutics intended to be released for local or systemic effects. In some implantable device embodiments, the device includes a microchannel intended to reduce intraocular pressure. In some implantable device embodiments, the device includes a microchannel intended to treat dry eye.

Abstract: A hydrophobic gel formulation for topical use, free of silicone products, comprising in weight percentage on the total weight of the formulation: from 10 to 50% of vitamin E, from 20 to 60% of a vegetable butter or a wax, from 10 to 30% triglyceride of caprylic and capric acid and from 3 to 10% of a gelling agent for lipids such as the triglyceride of palmitic and stearic acid.

Abstract: A composition for injection into a host is provided according to the embodiments of the present application. The composition consists of microparticles consisting essentially of an opioid antagonist and a polymeric binder selected from the group consisting of poly(glycolic acid), poly-d,l-lactic acid, poly-l-lactic acid, copolymers of the foregoing, poly(aliphatic carboxylic acids), copolyoxalates, polycaprolactone, polydioxanone, poly(ortho carbonates), poly(acetals), poly(lactic acid-caprolactone), polyorthoesters, poly(glycolic acid-caprolactone), polyanhydrides, and polyphosphazines; an injection vehicle, wherein said injection vehicle consists of water, a viscosity enhancing agent, a wetting agent, and a tonicity adjusting agent; and a steroidal anti-inflammatory agent.

Abstract: A microcapsule encapsulates a payload agent, the microcapsule having a microcapsule shell material that is rupturable (e.g., to release the encapsulated payload agent) via a retro-dimerization reaction.

Abstract: The present invention pertains to a complex including nanoparticles and, carried on the surface of the nanoparticles, a lysosomal enzyme inhibitor or kinase inhibitor shown by general formula (A) and a phospholipid mimetic substance shown by general formula (B). In general formula (A), n1 is an integer of 2-30, n2 is an integer of 2-30, the -S- terminal is a nanoparticle-carrying site, and R10 is a suicide substrate site or a kinase inhibition site. In general formula (B), n3 is an integer in the range of 2-30, and the -S- terminal is a nanoparticle-carrying site. The present invention provides a versatile system capable of efficiently delivering a drug to endolysosomes and allowing the drug to function at a low concentration on lysosomal enzymes, and an anticancer agent in which this system is used.

Abstract: Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C5-C18 alkyl, branched C5-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom. Methods for treating pulmonary hypertension (e.g., pulmonary arterial hypertension) and portopulmonary hypertension are also provided.

Abstract: An advantageous isolated morphic form of trilaciclib which is 2?-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7?,8?-dihydro-6?H-spiro[cyclohexane-1,9?-pyrazino[1?,2?:1,5]pyrrolo[2,3-d]pyrimidin]-6?-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.

Abstract: What is described is a compound of formula I consisting of a compound in which R1 is a branched chain alkyl consisting of 10 to 31 carbons; R2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons; L1 and L2 are the same or different, each a linear alkylene or alkenylene consisting of 2 to 20 carbons; X1 is S or O; R3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.

Abstract: An agent comprising: an algin crosslinked with acetal linkages; and at least one cation coupled to the crosslinked algin.

Abstract: Disclosed herein is a compound of Formula I, wherein R1 is a branched chain alkyl consisting of 10 to 31 carbons; R2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons, or a branched chain alkyl consisting of 10 to 31 carbons; L1 and L2 are the same or different, each a linear alkane of 1 to 20 carbons or a linear alkene of 2 to 20 carbons; X1 is S or O; R3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt or solvate thereof.

Abstract: Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

Abstract: A method and apparatus that enables the production of micron-scale free-standing bubbles made of liquids containing surfactants are provided. The method and apparatus of the invention overcomes the limitations of conventional bubble forming techniques by using a controlled cavitation process in a liquid media.

Abstract: The invention relates to an antimicrobial mixture containing 4-(3-ethoxy-4-hydroxy-phenyl)butan-2-one and an additional compound chosen from chlorhexidine digluconate, chlorhexidine hydrochloride and a polyhexamethylene biguanide salt, and also to a cosmetic composition containing such a mixture. Use in caring for, making up and cleansing keratin materials.

Abstract: A method of delivering a health care active having the steps of administering to a mammal in need of a health benefit or a treatment for a health condition a personal health care article and consuming the article. The article contains one or more filaments that contain a backbone material, a health care active and optionally aesthetic agents, extensional aids, plasticizers, and crosslinking agents.

Abstract: A composition to treat epidermal insults comprises suspended nanodiamonds. The nanodiamonds may be unagglomerated and ungraphenated detonation synthesis nanodiamonds at 2 nm to 4 nm in initial crystal size and 0.2%-0.5% composition weight. The nanodiamonds may be suspended homogeneously in medical grade Sea Buckthorn berry oil. The nanodiamonds may be suspended in group consisting of Sea Buckthorn berry oil, Sea Buckthorn seed oil, glycerin, olive oil, Dimethyl sulfoxide (DMSO), hand creams such as those sold under the tradename UDDERLY SMOOTH and WORKING HANDS (e.g., Udderly Smooth, Working Hands), hydrocortisone cream, triple antibiotic ointment, and combinations thereof. The nanodiamonds can be agglomerated crystals 30 nm to 50 nm in diameter.

Abstract: A coating composition containing a crosslinkable coating composition. The coating system comprises: ingredient A that has at least two protons that can be activated to form a Michael carbanion donor; ingredient B that functions as a Michael acceptor having at least two ethylenically unsaturated functionalities each activated by an electron-withdrawing group; and a catalyst system. In one embodiment, the catalyst system comprises diethyl carbonate, quaternary ammonium hydroxide or quaternary ammonium alkoxide, ethanol and 4-6 wt. % water. In another embodiment, the catalyst system comprises carbon dioxide, quaternary ammonium hydroxide or quaternary ammonium alkoxide, ethanol and 2-4 wt. % water. In certain embodiments, the coating composition optionally further comprising ammonium carbamate (H2NR8R9+—OC?ONR8R9), wherein R8R9 are each independently selected from hydrogen, a linear or branched substituted or unsubstituted alkyl group having 1 to 22 carbon atoms; 1 to 8 carbon atoms; 1 to 3 carbon atoms.

Abstract: The present invention is on a cosmetic composition for improving color brilliance and wash fastness of artificially-colored keratin fibers. The effect is achieved by the combination of pyrrolidone carboxylic acid esters, pyrrolidone carboxylic acid and/or its salts, and amodimethicone microemulsion. A process for treating keratin fibers, a use of the composition and well as a kit-of-parts is disclosed.